The Promise of Epigenetic Therapeutics in Alcohol-Associated Hepatitis ft. DURECT President and CEO Dr. James Brown

Xtalks Life Science Podcast

In this episode, Ayesha spoke with James E. Brown, DVM, co-founder, President and CEO of DURECT.

DURECT is pioneering a therapeutic strategy by leveraging the potential of epigenetic modulation to alter the trajectory of severe and life-threatening conditions like acute organ injury and cancer.

The company is specifically focused on the development of an epigenetic modulator, larsucosterol (DUR-928) for the treatment of alcohol-associated hepatitis (AH). The therapeutic has shown promising results in human studies, including a Phase IIb trial in AH patients.

Dr. Brown co-founded DURECT in February 1998 and has served as President, CEO and a Director since June 1998. Dr. Brown has worked in various leadership positions, including as Vice President of Biopharmaceutical and Implant Research and Development at ALZA Corporation from 1995 to 1998 and various leadership roles at Syntex Corporation, now Roche. Dr. Brown holds a Doctor of Veterinary Medicine (DVM) from the University of California, Davis, where he also conducted postgraduate work in pharmacology and toxicology.

Tune into the episode to learn more about the promise of next generation epigenic modulators, including DURECT’s innovative epigenetic therapeutic approach.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured